For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf